Patents Assigned to Benitec Biopharma Limited
-
Patent number: 11234994Abstract: The present disclosure relates to RNA interference (RNAi) reagents for treatment of oculopharyngeal muscular dystrophy (OPMD), compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto.Type: GrantFiled: April 13, 2017Date of Patent: February 1, 2022Assignee: Benitec Biopharma LimitedInventors: David Suhy, Michael Graham, Capucine Trollet, Alberto Malerba, John George Dickson
-
Patent number: 10898505Abstract: This disclosure relates to RNA interference (RNAi) reagents for treatment of hepatitis B virus (HBV) infection, compositions comprising same, and use thereof to treat individuals infected with HBV.Type: GrantFiled: May 6, 2016Date of Patent: January 26, 2021Assignee: Benitec Biopharma LimitedInventors: Tin Mao, Shih-Chu Kao, David Suhy, Michael Graham
-
Publication number: 20190338285Abstract: This disclosure relates to RNA interference (RNAi) reagents for treatment of hepatitis B virus (HBV) infection, compositions comprising same, and use thereof to treat individuals infected with HBV. The reagents are artificial miRNA (shmiRNA) used alone or in combination with additional shmiRNA or shRNA.Type: ApplicationFiled: May 5, 2017Publication date: November 7, 2019Applicant: BENITEC BIOPHARMA LIMITEDInventors: Tin MAO, David SUHY
-
Patent number: 10000753Abstract: This invention is directed to an RNA interference (RNAi) agent and the use of that RNAi agent to treat Age-related Macular Degeneration, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agent is a DNA-directed RNA interference (ddRNAi) agent (being an RNA molecule), together with an expression cassette or construct to express that agent in a cell (including in vivo), for inhibiting, preventing or reducing expression of an AMD associated gene. Preferably that AMD associated gene is one that is associated with wet AMD.Type: GrantFiled: January 8, 2014Date of Patent: June 19, 2018Assignee: BENITEC BIOPHARMA LIMITEDInventors: David Suhy, Tin Mao, Shih-Chu Kao
-
Patent number: 9790502Abstract: This invention is directed to a RNA interference (RNAi) agent and the use of that RNAi agent to treat hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, where the agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some forms of the invention, the agent has more than one effector sequence. Multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.Type: GrantFiled: July 11, 2016Date of Patent: October 17, 2017Assignee: BENITEC BIOPHARMA LIMITEDInventors: Michael Wayne Graham, Peter French, York YuanYuan Zhu, YiXiang Lu, TieJun Li, YunCheng Sun, XiaoJun Tang, Li Shan
-
Patent number: 9518260Abstract: The disclosure relates to an RNA interference (RNAi) agent and the use of that RNAi agent to treat chronic pain in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The DNA-directed RNA interference (ddRNAi) agent for inhibiting expression of one or more target sequences in a pain associated gene comprises, one or more effector sequence sequences and effector complement sequences of at least 17 nucleotides in length, wherein the effector sequence is substantially complementary to the predicted transcript of a target sequence within a pain associated gene.Type: GrantFiled: February 28, 2013Date of Patent: December 13, 2016Assignee: Benitec Biopharma LimitedInventors: Peter William French, Michael Wayne Graham
-
Patent number: 9410154Abstract: RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.Type: GrantFiled: June 5, 2015Date of Patent: August 9, 2016Assignee: BENITEC BIOPHARMA LIMITEDInventors: Michael Wayne Graham, Peter French, York YuanYuan Zhu, YiXiang Lu, TieJun Li, YunCheng Sun, XiaoJun Tang, Li Shan
-
Patent number: 9080174Abstract: RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.Type: GrantFiled: October 27, 2011Date of Patent: July 14, 2015Assignee: BENITEC BIOPHARMA LIMITEDInventors: Michael Wayne Graham, Peter French, York YuanYuan Zhu, Yixiang Lu, TieJun Li, Yuncheng Sun, XiaoJun Tang, Li Shan
-
Publication number: 20130296401Abstract: RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.Type: ApplicationFiled: October 27, 2011Publication date: November 7, 2013Applicants: BIOMICS BIOTECHNOLOGIES CO., LTD, BENITEC BIOPHARMA LIMITEDInventors: Michael Wayne Graham, Peter French, York YuanYuan Zhu, Lu YiXiang, Li TieJun, Sun YunCheng, Tang XiaoJun, Shan Li
-
Patent number: 8129510Abstract: Methods and compositions for expressing a gene or nucleotide sequence of interest are provided. The compositions include an expression cassette that includes a synthetic enhancer, a transthyretin promoter, and a nucleotide sequence operably under the control of the synthetic enhancer and the transthyretin promoter. The expression cassette may be used in an adeno-associated viral (AAV) vector, such as a self-complementary AAV vector.Type: GrantFiled: March 30, 2007Date of Patent: March 6, 2012Assignees: The Board of Trustees of the Leland Stanford Junior University, Benitec Biopharma LimitedInventors: Mark Kay, Micheal Hebert, Petrus Wilhelmus Roelvink, David A. Suhy